Aggressive angiomyxoma of the pelvis with high Ki-67 expression: a case report and literature review

Purpose: As a benign tumor, aggressive angiomyxoma (AA) of the pelvis has a high local recurrence rate within several years after surgery. Radiation therapy has been proved to be ineffective for preventing recurrence. Ki-67 is a famous marker of cell proliferation for many cancers. High Ki-67 expression was correlated with radiosensitivity in other cancers. For aggressive angiomyxoma, Ki-67 expression and its relationship with radiosensitivity were rarely reported. Therefore, the authors present a case of AA with high Ki-67 expression. Materials and Methods: A 30-year-old woman presented with menorrhagia and a slowly growing mass on the right side of the pelvis. She was diagnosed with AA based on clinical features, radiological investigation, histopathology, and immunohistochemical stains. The tumor was excised successfully. Staining for Ki-67 was approximately 30% positive. After the excision, the patient was treated with a total dose of 48 Gy in 24 fractions using three-dimensional conformal radiation therapy. Results: The patient had local recurrent tumor at 16 months of follow-up after the surgery. Conclusion: AA of the pelvis has a high local recurrence rate within several years after surgery. Whether the recurrence was associated with high Ki-67 expression needs more clinical cases observations in the future.

Aggressive angiomyxoma; Case report; Ki-67; Pelvis; Radiotherapy

[1] Lee K.A., Seo J.W., Yoon N.R., Lee J.W., Kim B.G., Bae D.S.: “Aggressive angiomyxoma of the vulva: A case report”. Obstet. Gynecol. Sci., 2014, 57, 164.

[2] Steeper T.A., Rosai J.: “Aggressive angiomyxoma of the female pelvis and perineum. Report of nine cases of a distinctive type of gynecologic soft-tissue neoplasm”. Am. J. Surg. Pathol., 1983, 7, 463.

[3] Xie Y., Chen L., Ma X., Li H., Gu L., Gao Y., et al.: “Prognostic and clinicopathological role of high Ki-67 expression in patients with renal cell carcinoma: a systematic review and meta-analysis”. Sci. Rep., 2017, 7, 44281.

[4] Piura B., Shaco-Levy R.: “Pedunculated aggressive angiomyxoma arising from the vaginal suburethral area: case report and review of literature”. Eur. J. Gynaecol. Oncol., 2005, 26, 568.

[5] Outwater E.K., Marchetto B.E., Wagner B.J., Siegelman E.S.: “Aggressive angiomyxoma: findings on CT and MR imaging. AJR Am. J. Roentgenol., 1999, 172, 435.

[6] Jeyadevan N.N., Sohaib S.A., Thomas J.M., Jeyarajah A., Shepherd J.H., Fisher C.: “Imaging features of aggressive angiomyxoma”. Clin. Radiol., 2003, 58, 157.

[7] Narang S., Kohli S., Kumar V., Chandoke R.: “Aggressive angiomyxoma with perineal herniation”. J. Clin. Imaging Sci., 2014, 4, 23.

[8] Surabhi V.R., Garg N., Frumovitz M., Bhosale P., Prasad S.R., Meis J.M.: “Aggressive angiomyxomas: a comprehensive imaging review with clinical and histopathologic correlation”. AJR Am. J. Roentgenol., 2014, 202, 1171.

[9] Okamoto Y., Tanaka Y.O., Nishida M., Tsunoda H., Yoshikawa H., Itai Y.: “MR imaging of the uterine cervix: imaging-pathologic correlation”. Radiographics, 2003, 23, 425.

[10] Amin A., El Badawy S., Bull A.: “Aggressive angiomyxoma of the vulva”. J. Obstet. Gynaecol., 2013, 33, 325.

[11] Benson J.C., Gilles S., Sanghvi T., Boyum J., Niendorf E.: “Aggressive angiomyxoma: case report and review of the literature”. Radiol. Case Rep., 2016, 11, 332.

[12] Han-Geurts I.J., van Geel A.N., van Doorn L., Bakker M.D., Eggermont A.M., Verhoef C.: “Aggressive angiomyxoma: multimodality treatments can avoid mutilating surgery”. Eur. J. Surg. Oncol., 2006, 32, 1217.

[13] Silverman J.S., Albukerk J., Tamsen A.: “Comparison of angiomyofibroblastoma and aggressive angiomyxoma in both sexes: four cases composed of bimodal CD34 and factor XIIIa positive dendritic cell subsets”. Pathol. Res. Pract., 1997, 193, 673.

[14] Ahmed W.A., Suzuki K., Imaeda Y., Horibe Y.: “Ki-67, p53 and epidermal growth factor receptor expression in early glottic cancer involving the anterior commissure treated with radiotherapy”. Auris Nasus Larynx, 2008, 35, 213.

[15] Couture C., Raybaud-Diogene H., Tetu B., Bairati I., Murry D., Allard J., et al.: “p53 and Ki-67 as markers of radioresistance in head and neck carcinoma”. Cancer, 2002, 94, 713.